Skip to main content

Ask RayNew Trends Ads Appearances Podcasts API

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.

Medical Digest & Congress Report

Medical Digest & Congress Report

Effect of CagriSema on Bone Biomarkers in Inadequately Controlled Type 2 Diabetes: REIMAGINE 2 - report from EASD 2026

Oct 13, 2026 · 6 min · 5 segments

Dr. Martin Haluzík presents key findings from the REIMAGINE 2 trial evaluating CagriSema at the EASD 2026 Congress. This brief highlights clinical data on the impact of dual amylin and GLP-1 receptor…

Dr. Martin Haluzík presents key findings from the REIMAGINE 2 trial evaluating CagriSema at the EASD 2026 Congress. This brief highlights clinical data on the impact of dual amylin and GLP-1 receptor agonism on bone turnover markers, overall bone health, and metabolic parameters in participants with inadequately controlled type 2 diabetes. Video: https://medicaldigest.org/scientific-contents/interview:effect-cagrisema-bone-biomarkers-inadequately-controlled-type-2-diabetes-reimagine-2

Dr. Martin Haluzík presents key findings from the REIMAGINE 2 trial evaluating CagriSema at the EASD 2026 Congress. This brief highlights clinical data on the impact of dual amylin and GLP-1 receptor…

Speakers: Martin HaluzíkGuestClosing PresenterHost

Top entities: Cagrilintide/semaglutide×9 European Association for the Study of Diabetes×4 Hemoglobin A1C×3 Bone remodeling GLP-1 receptor agonist×3

Introducing CagriSema0:30 – 1:27

M

Martin HaluzíkGuest

0:30

And I also have had the pleasure of presenting the data on the change of bone biomarkers in patients treated with Cagri-Sema or Cagrelin-Tide-Semaglutide combination within the REIMAGINE 2 trial.

M

Martin HaluzíkGuest

0:45

So maybe let me start with making you more familiar with the CAGRY-SEMA fixed ratio combination.

M

Martin HaluzíkGuest

0:52

So CAGRY-SEMA is the combination of the CAGRYLINTIDE which is the agonist of the amylin receptor and also importantly from the bone metabolism point of view of the calcitonin receptor.

M

Martin HaluzíkGuest

1:05

So it's a dual agonist and it's combined with semaglutide that we all know very well as a treatment for obesity and type 2 diabetes.

M

Martin HaluzíkGuest

1:16

So semaglutide, as you know, is a GLP-1 receptor agonist.

M

Martin HaluzíkGuest

1:20

And CagriSema is now within the phase 3 trials for the treatment of both diabetes and obesity.

Cagrilintide/semaglutideEntityDrug
95%9 mentions
European Association for the Study of DiabetesOrganization
85%4 mentions
Hemoglobin A1CEntityChemical compound
75%3 mentions
Bone remodelingEntity
65%1 mention
GLP-1 receptor agonistEntityMedication
55%3 mentions
Institute of Clinical and Experimental MedicineHospitalClinic in Prague, Czechia
45%2 mentions
PragueLandmarkCapital of the Czech Republic
35%2 mentions
SemaglutideEntityMedication
25%2 mentions
Czech RepublicCountryCountry in Europe
15%1 mention
Sodium/glucose cotransporter 2EntityProtein
5%1 mention

Chronic DiseasesHealth
Randomized Clinical TrialsScience > Clinical Research
Incretin-Based and Amylin-Based TherapyHealthcare > Medical Treatment > Pharmacotherapy
Phase 3 Diabetes and Obesity TrialsScience > Clinical Research > Randomized Clinical Trials
REIMAGINE 2 Comparative Efficacy TrialScience > Clinical Research > Randomized Clinical Trials > Phase 3 Diabetes and Obesity Trials
Bone MetabolismHealth > Skeletal Health
Bone Turnover BiomarkersHealth > Skeletal Health > Bone Metabolism
Skeletal HealthHealth
Weight ManagementHealth > Metabolism
Clinical ResearchScience
Medical TreatmentHealthcare
Type 2 DiabetesHealth > Chronic Diseases > Diabetes
DiabetesHealth > Chronic Diseases
MetabolismHealth
Health
Science
Healthcare
PharmacotherapyHealthcare > Medical Treatment

Introducing CagriSema0:30 – 1:27

M

Martin HaluzíkGuest

0:30

And I also have had the pleasure of presenting the data on the change of bone biomarkers in patients treated with Cagri-Sema or Cagrelin-Tide-Semaglutide combination within the REIMAGINE 2 trial.

M

Martin HaluzíkGuest

0:45

So maybe let me start with making you more familiar with the CAGRY-SEMA fixed ratio combination.

M

Martin HaluzíkGuest

0:52

So CAGRY-SEMA is the combination of the CAGRYLINTIDE which is the agonist of the amylin receptor and also importantly from the bone metabolism point of view of the calcitonin receptor.

M

Martin HaluzíkGuest

1:05

So it's a dual agonist and it's combined with semaglutide that we all know very well as a treatment for obesity and type 2 diabetes.

M

Martin HaluzíkGuest

1:16

So semaglutide, as you know, is a GLP-1 receptor agonist.

M

Martin HaluzíkGuest

1:20

And CagriSema is now within the phase 3 trials for the treatment of both diabetes and obesity.

Sign up to see more

The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode

Create an account Already have an account? Log in

No account is needed to search Radar.